insulin lispro

This medicine is now withdrawn from use in the European Union.


The marketing authorisation for Liprolog has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 01/08/2001

Authorisation details

Product details
Agency product number
Active substance
insulin lispro
International non-proprietary name (INN) or common name
insulin lispro
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Eli Lilly and Company Limited
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Kingsclere Road
Hants RG21 6XA
United Kingdom

Product information

19/02/2001 Liprolog - EMEA/H/C/000143 -

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Drugs used in diabetes

  • Insulins and analogues for injection, fast-acting

Therapeutic indication

For the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Liprolog is also indicated for the initial stabilization of diabetes mellitus. Liprolog is a short acting insulin and may be used in conjunction with a longer acting human insulin. Liprolog is indicated for preprandial administration.

How useful was this page?

Add your rating